Evidence map›Paper›PMID 41402308›Full record

ArticleNature communications2025

Enzymatic synthesis of key RNA therapeutic building blocks using simple phosphate donors.

Qinglong Meng, Caecilie Benckendorff, Charlotte Morrill, Ying Zhuo, Annette Egerström, Aisling Ní Cheallaigh, Sasha R Derrington, Richard Obexer, Mary Ortmayer, Colin W Levy and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qinglong MengManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK.
Caecilie BenckendorffCentre for Glycoscience and School of Chemical and Physical Sciences, Keele University, Keele, Staffordshire, UK.ORCID http://orcid.org/0009-0009-1495-8424
Charlotte MorrillManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK.
Ying ZhuoManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK.
Annette EgerströmManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK.ORCID http://orcid.org/0009-0001-3145-5978
Aisling Ní CheallaighCentre for Glycoscience and School of Chemical and Physical Sciences, Keele University, Keele, Staffordshire, UK.
Sasha R DerringtonManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK.
Richard ObexerManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-4940-3543
Mary OrtmayerManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK.
Colin W LevyManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK.
James D FinniganProzomix Ltd, Haltwhistle, UK.ORCID http://orcid.org/0000-0002-8514-784X
Simon J CharnockProzomix Ltd, Haltwhistle, UK.
Nicholas J TurnerManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-8708-0781
Gavin J MillerCentre for Glycoscience and School of Chemical and Physical Sciences, Keele University, Keele, Staffordshire, UK.ORCID http://orcid.org/0000-0001-6533-3306
Sarah L LovelockManchester Institute of Biotechnology and Department of Chemistry, University of Manchester, Manchester, UK. sarah.lovelock@manchester.ac.uk.ORCID http://orcid.org/0000-0002-4584-3189

Funding

RCUK | Medical Research Council (MRC) MR/W029324/1Research Councils UK (RCUK) MR/T041722/1
6 · The paper itself

Abstract

The rapid emergence of RNA therapeutics has highlighted the need for more efficient, scalable and sustainable methods for their manufacture. Biocatalytic approaches hold particular promise, but rely on a secure, sustainable and low-cost supply of nucleoside triphosphate (NTP) building blocks, including those containing chemical modifications. Here we report the development of a biocatalytic approach and engineered enzymes to convert widely available nucleosides into NTPs featuring pharmaceutically relevant modifications using inexpensive phosphate donors. Importantly our strategy obviates the need for ATP as a phosphate donor that complicates NTP isolation using existing methods. To showcase the utility of our approach, we employ an engineered acid phosphatase, polyphosphate kinase and acetate kinase to produce 2'-O-methoxyethyl-ATP (2'-MOE-ATP) and 2'-fluoro-ATP, key building blocks of commercial therapeutics. Finally, we show that crude NTPs from our process can be used directly in enzymatic oligonucleotide synthesis, obviating the need for costly NTP isolation or purification steps.

Indexed as

Adenosine TriphosphatePhosphatesRNAAcid PhosphataseBiocatalysisPhosphotransferases (Alcohol Group Acceptor)Phosphotransferases (Phosphate Group Acceptor)Acid PhosphataseAdenosine TriphosphatePhosphatesPhosphotransferases (Alcohol Group Acceptor)Phosphotransferases (Phosphate Group Acceptor)polyphosphate kinaseRNA

Identifiers

PMID41402308
PMCPMC12816578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.